Similar articles for PMID: 25594040

Year	Number of Results
1978	1
1992	1
2005	1
2006	3
2007	3
2008	2
2009	4
2010	5
2011	2
2012	4
2013	2
2014	4
2015	4
2016	4
2017	12
2018	6
2019	7
2020	4
2021	1
2024	0

1

Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Carlino MS, Todd JR, Rizos H. Carlino MS, et al. Oncoscience. 2014 Jun 6;1(6):423-6. doi: 10.18632/oncoscience.51. eCollection 2014. Oncoscience. 2014. PMID: 25594040 Free PMC article.

2

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

Todd JR, Scurr LL, Becker TM, Kefford RF, Rizos H. Todd JR, et al. Oncogene. 2014 Jan 9;33(2):236-45. doi: 10.1038/onc.2012.562. Epub 2012 Dec 17. Oncogene. 2014. PMID: 23246970

3

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Ascierto PA, et al. J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1. J Transl Med. 2015. PMID: 26619946 Free PMC article.

4

Melanoma mutagenesis and aberrant cell signaling.

Bello DM, Ariyan CE, Carvajal RD. Bello DM, et al. Cancer Control. 2013 Oct;20(4):261-81. doi: 10.1177/107327481302000404. Cancer Control. 2013. PMID: 24077403 Free article. Review.

5

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

Smalley KS, Sondak VK, Weber JS. Smalley KS, et al. Histol Histopathol. 2009 May;24(5):643-50. doi: 10.14670/HH-24.643. Histol Histopathol. 2009. PMID: 19283671 Review.

6

Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

Bosbach B, Rossi F, Yozgat Y, Loo J, Zhang JQ, Berrozpe G, Warpinski K, Ehlers I, Veach D, Kwok A, Manova K, Antonescu CR, DeMatteo RP, Besmer P. Bosbach B, et al. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8448-E8457. doi: 10.1073/pnas.1711449114. Epub 2017 Sep 18. Proc Natl Acad Sci U S A. 2017. PMID: 28923937 Free PMC article.

7

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.

Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P. Gebreyohannes YK, et al. Clin Exp Med. 2019 May;19(2):201-210. doi: 10.1007/s10238-018-0541-2. Epub 2018 Dec 6. Clin Exp Med. 2019. PMID: 30523507

8

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Jiang X, et al. Clin Cancer Res. 2008 Dec 1;14(23):7726-32. doi: 10.1158/1078-0432.CCR-08-1144. Clin Cancer Res. 2008. PMID: 19047099

9

Somatic activation of KIT in distinct subtypes of melanoma.

Curtin JA, Busam K, Pinkel D, Bastian BC. Curtin JA, et al. J Clin Oncol. 2006 Sep 10;24(26):4340-6. doi: 10.1200/JCO.2006.06.2984. Epub 2006 Aug 14. J Clin Oncol. 2006. PMID: 16908931

10

Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling.

Bahlawane C, Schmitz M, Letellier E, Arumugam K, Nicot N, Nazarov PV, Haan S. Bahlawane C, et al. Cell Signal. 2017 Jan;29:138-149. doi: 10.1016/j.cellsig.2016.10.009. Epub 2016 Oct 21. Cell Signal. 2017. PMID: 27777072 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

65 results

Results by year